<ul>
<li>条件性批准延长至 2026 年 12 月，用于治疗犬类化疗引起的腹泻（CID）</li>
</ul>
<ul>
<li>CID 确认有效性试验预计于 2026 年 2 月结束，提前于 FDA 的 6 月截止日期 - 目前已招募 51 只犬，预计再招募约 49 只</li>
</ul>
<p>加利福尼亚州旧金山 / ACCESS Newswire /2025 年 12 月 10 日/ Jaguar Health, Inc.(NASDAQ:JAGX) 今天宣布，美国食品药品监督管理局（FDA）已续发 <strong>Canalevia-CA1</strong>（crofelemer 缓释片）的条件性批准。Canalevia-CA1 是该公司用于治疗犬类化疗引起的腹泻（CID）的处方药，已通过多家领先的兽医分销商在美国上市，包括 <strong>Chewy</strong>。条件性批准的续期有效至 2026 年 12 月 21 日。</p>
<p>&#34;Canalevia-CA1 是兽医界和数千只经历 CID 的犬类的重要处方药。我们对这一条件性批准的续期感到非常高兴，根据 FDA 的规定，这是 Canalevia-CA1 针对犬类 CID 适应症的第五年也是最后一年允许的条件性批准。当动物药物获得条件性批准时，FDA 要求在 5 年内进行确认试验，以提供所需的有效性实质证据，以便获得该药物的完全批准，&#34;Jaguar 的临床前和非临床研究副总裁 Michael Guy 博士（D.V.M., M.S., Ph.D.）表示。&#34;如前所述，我们的 Canalevia-CA1 针对犬类 CID 的全面有效性研究正在进行中，这一最近的条件性批准续期是因为我们能够展示出朝着生成所需数据的积极进展。&#34;</p>
<p>&#34;腹泻是犬类和接受癌症治疗的人们高度被忽视且未满足的医疗需求，&#34;Jaguar 的总裁兼首席执行官 Lisa Conte 表示。&#34;Jaguar 深切致力于支持正在接受癌症治疗的人和动物的生活质量。&#34;</p>
<p><strong>关于条件性批准和完全批准</strong></p>
<p>Canalevia-CA1 于 2021 年 12 月首次获得 FDA 的 <strong>条件性批准</strong>，用于治疗犬类 CID。FDA 的条件性批准允许药品公司在证明药物符合完全批准的&#34;实质证据&#34;有效性标准之前，合法推广、广告和销售该动物药物。条件性批准有效期为一年，最多可续期四次，总共五年的条件性批准。为了获得 FDA 的续期，该公司必须展示出朝着证明&#34;实质证据有效性&#34;的积极进展。在收集剩余的有效性数据后，该公司再向 FDA 申请完全批准。FDA 审核申请，并在适当的情况下完全批准该药物。</p>
<p><strong>关于 Canalevia®-CA1</strong></p>
<p>Canalevia-CA1 含有 crofelemer，这是 Jaguar 从_Croton lechleri_树上可持续采集的创新植物药，能够调节胃肠道中的氯通道以减少腹泻。重要的是，Canalevia 并不是抗生素药物。抗生素在人体和动物中的过度使用和误用导致了抗生素耐药菌的产生。Canalevia-CA1 目前在 FDA 的申请编号 141-552 下获得条件性批准，是一种可以口服给药的片剂，每天可服用两次，最多可持续三天，可用于犬类 CID 的家庭治疗。</p>
<p><strong>关于犬类化疗引起的腹泻（CID）</strong></p>
<p>根据美国兽医医学协会的数据显示，约四分之一的犬类在其生命的某个阶段会发展为癌症。近一半的 10 岁以上犬类会发展为癌症。根据美国国立卫生研究院的国家癌症研究所，每年在美国约有 600 万只犬类被诊断为新癌症。</p>
<p>由于化疗药物数量的增加，化疗正迅速成为兽医医学中使用最广泛的癌症治疗方法。研究发现，CID 的发生率是接受癌症治疗的犬类中三种最常见的副作用之一，管理腹泻等副作用对于维持成功的癌症治疗至关重要。超过一半的参与 Jaguar 赞助调查的美国兽医报告称，CID 干扰了他们患者的化疗治疗计划，表明对有效治疗 CID 的产品存在未满足的需求。</p>
<p><strong>关于 Canalevia®-CA1 的重要安全信息</strong></p>
<p>仅供犬类口服使用。不适用于人类。将 Canalevia-CA1（crofelemer 缓释片）放在儿童和其他动物无法接触的安全位置。如人类意外摄入，请咨询医生。不得用于已知对 crofelemer 过敏的犬类。在使用 Canalevia-CA1 之前，排除腹泻的感染性病因。Canalevia-CA1 是一种条件性批准的药物，适用于治疗犬类化疗引起的腹泻。最常见的不良反应包括食欲减退、活动减少、脱水、腹痛和呕吐。</p>
<p><strong>注意：</strong> 联邦法律限制该药物仅由持证兽医使用或根据其指示使用。仅按指示使用。违反联邦法律，使用本产品不得与标签指示不符。根据申请编号 141-552，FDA 条件性批准，待完全证明有效性。</p>
<p><strong>关于 Jaguar Health 公司家族</strong></p>
<p>Jaguar Health, Inc.（Jaguar）是一家商业阶段的制药公司，专注于开发可持续来源于雨林地区植物的新型专利处方药，旨在为人类和动物提供针对胃肠道不适的治疗，特别是与肠道过度活跃相关的症状，包括慢性虚弱性腹泻、急迫感、肠失禁和痉挛性疼痛。Jaguar 旗下的 Napo Pharmaceuticals（Napo）专注于开发和商业化人用处方药，以支持和管理多种复杂疾病状态下被忽视的胃肠道症状。Jaguar 旗下的 Napo Therapeutics 是一家意大利公司，Jaguar 于 2021 年在意大利米兰成立，专注于扩大 crofelemer 在欧洲的使用，特别是针对孤儿疾病。Jaguar Animal Health 是 Jaguar 的商标名称。Magdalena Biosciences 是 Jaguar 与 Filament Health Corp.共同成立的合资企业，源于 Jaguar 的 Entheogen Therapeutics Initiative（ETI），专注于开发源自植物的针对心理健康的处方药。</p>
<p>有关更多信息：</p>
<p>Jaguar Health，请访问 https://jaguar.health</p>
<p>Napo Pharmaceuticals，请访问 napopharma.com</p>
<p>Napo Therapeutics，请访问 napotherapeutics.com</p>
<p>Magdalena Biosciences，请访问 magdalenabiosciences.com</p>
<p>Canalevia-CA1，请访问 canalevia.com</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿中的某些声明构成 “前瞻性声明”。这些包括关于 Jaguar 期望公司正在进行的试验将提供治疗犬类 CID 所需的有效性充分证据的声明，并预计将在 2026 年 2 月结束，参与犬只总数约为 100 只。在某些情况下，您可以通过诸如 “可能”、“将”、“应该”、“期望”、“计划”、“目标”、“预期”、“能够”、“打算”、“针对”、“项目”、“考虑”、“相信”、“估计”、“预测”、“潜在” 或 “继续” 等术语或这些术语的否定形式或其他类似表达来识别前瞻性声明。本声明中的前瞻性声明仅为预测。Jaguar 在很大程度上基于其当前的期望和对未来事件的预测来制定这些前瞻性声明。这些前瞻性声明仅在本声明发布之日有效，并且受到多种风险、不确定性和假设的影响，其中一些无法预测或量化，某些超出了 Jaguar 的控制范围。除非法律要求，Jaguar 不打算公开更新或修订本声明中包含的任何前瞻性声明，无论是由于任何新信息、未来事件、情况变化或其他原因。</p>
<p>1 &#34;宠物中的癌症。&#34; 美国兽医医学协会，2021 年，https://www.avma.org/resources/pet-owners/petcare/cancer-pets</p>
<p>2 Mason SL, Grant IA, Elliott J, Cripps P, Blackwood L. 在犬只中使用或不使用 maropitant 后，vincristine 或 cyclophosphamide 引起的胃肠道毒性：一项前瞻性随机对照研究。J Small Anim Pract. 2014;55:391-398</p>
<p><strong>联系方式：</strong></p>
<p>hello@jaguar.health</p>
<p>Jaguar-JAGX</p>
<p><strong>来源：</strong> Jaguar Health, Inc.</p>
<p>查看原始新闻稿，请访问 ACCESS Newswire</p>

JAGX

<p>Jaguar Health 宣布 FDA 已续期对 Canalevia-CA1 的有条件批准，该药物用于治疗犬只化疗引起的腹泻，续期至 2026 年 12 月。确认有效性试验预计将在 2026 年 2 月结束。Canalevia-CA1 可通过美国主要兽医分销商获得，对经历化疗引起腹泻的犬只至关重要。此次续期标志着有条件批准的第五年也是最后一年，全面批准将取决于试验结果</p>

<ul>
<li>Conditional approval extended through December 2026 for the treatment of CID in dogs</li>
</ul>
<div class="lb-trans"><ul>
<li>条件性批准延长至 2026 年 12 月，用于治疗犬类化疗引起的腹泻（CID）</li>
</ul>
</div><ul>
<li>CID confirmatory effectiveness trial expected to conclude in February 2026, ahead of FDA's June deadline - 51 dogs enrolled to date; ~49 more expected</li>
</ul>
<div class="lb-trans"><ul>
<li>CID 确认有效性试验预计于 2026 年 2 月结束，提前于 FDA 的 6 月截止日期 - 目前已招募 51 只犬，预计再招募约 49 只</li>
</ul>
</div><p>SAN FRANCISCO, CA / ACCESS Newswire / December 10, 2025 / Jaguar Health, Inc.(NASDAQ:JAGX) today announced that the U.S. Food and Drug Administration (FDA) has granted renewal of the conditional approval for <strong>Canalevia-CA1</strong> (crofelemer delayed-release tablets). Canalevia-CA1, the company's prescription drug for the treatment of chemotherapy-induced diarrhea (CID) in dogs, is available from multiple leading veterinary distributors in the U.S., including <strong>Chewy</strong>. The renewal of conditional approval is in effect until December 21, 2026.</p>
<div class="lb-trans"><p>加利福尼亚州旧金山 / ACCESS Newswire /2025 年 12 月 10 日/ Jaguar Health, Inc.(NASDAQ:JAGX) 今天宣布，美国食品药品监督管理局（FDA）已续发 <strong>Canalevia-CA1</strong>（crofelemer 缓释片）的条件性批准。Canalevia-CA1 是该公司用于治疗犬类化疗引起的腹泻（CID）的处方药，已通过多家领先的兽医分销商在美国上市，包括 <strong>Chewy</strong>。条件性批准的续期有效至 2026 年 12 月 21 日。</p>
</div><p>&#34;Canalevia-CA1 is an important prescription drug for the veterinary community and the thousands of dogs experiencing CID. We're very pleased about this conditional approval renewal, which, per FDA regulations, is for the fifth and final allowable year of conditional approval for Canalevia-CA1 for the CID indication in dogs. When an animal drug receives conditional approval, the FDA requires that a confirmatory trial take place within 5 years to provide the substantial evidence of effectiveness required for full approval of the drug for the indication,&#34; said Dr. Michael Guy, D.V.M., M.S., Ph.D., Jaguar's Vice President of Preclinical and Nonclinical Studies. &#34;As announced, our full effectiveness study of Canalevia-CA1 for the treatment of CID in dogs is underway, and this recent conditional approval renewal was granted because we were able to demonstrate active progress toward generating this required data.&#34;</p>
<div class="lb-trans"><p>&#34;Canalevia-CA1 是兽医界和数千只经历 CID 的犬类的重要处方药。我们对这一条件性批准的续期感到非常高兴，根据 FDA 的规定，这是 Canalevia-CA1 针对犬类 CID 适应症的第五年也是最后一年允许的条件性批准。当动物药物获得条件性批准时，FDA 要求在 5 年内进行确认试验，以提供所需的有效性实质证据，以便获得该药物的完全批准，&#34;Jaguar 的临床前和非临床研究副总裁 Michael Guy 博士（D.V.M., M.S., Ph.D.）表示。&#34;如前所述，我们的 Canalevia-CA1 针对犬类 CID 的全面有效性研究正在进行中，这一最近的条件性批准续期是因为我们能够展示出朝着生成所需数据的积极进展。&#34;</p>
</div><p>&#34;Diarrhea is a highly neglected and unmet medical need in dogs and people undergoing cancer treatment,&#34; said Lisa Conte, Jaguar's president and CEO. &#34;Jaguar is deeply committed to supporting the quality of life of people and animals undergoing cancer treatment.&#34;</p>
<div class="lb-trans"><p>&#34;腹泻是犬类和接受癌症治疗的人们高度被忽视且未满足的医疗需求，&#34;Jaguar 的总裁兼首席执行官 Lisa Conte 表示。&#34;Jaguar 深切致力于支持正在接受癌症治疗的人和动物的生活质量。&#34;</p>
</div><p><strong>About Conditional Approval and Full Approval</strong></p>
<div class="lb-trans"><p><strong>关于条件性批准和完全批准</strong></p>
</div><p>Canalevia-CA1 initially received <strong>conditional approval</strong> in December 2021 from the FDA for the treatment of CID in dogs. FDA's conditional approval allows a drug company to legally promote, advertise and sell the animal drug for the labeled uses before proving it meets the &#34;substantial evidence&#34; standard of effectiveness for full approval. The conditional approval is valid for one year, with up to four annual renewals, for a total of five years of conditional approval. To receive a renewal from the FDA, the company must show active progress toward proving &#34;substantial evidence of effectiveness&#34; for full approval. After collecting the remaining effectiveness data, the company then applies to the FDA for full approval. The FDA reviews the application and, if appropriate, fully approves the drug.</p>
<div class="lb-trans"><p>Canalevia-CA1 于 2021 年 12 月首次获得 FDA 的 <strong>条件性批准</strong>，用于治疗犬类 CID。FDA 的条件性批准允许药品公司在证明药物符合完全批准的&#34;实质证据&#34;有效性标准之前，合法推广、广告和销售该动物药物。条件性批准有效期为一年，最多可续期四次，总共五年的条件性批准。为了获得 FDA 的续期，该公司必须展示出朝着证明&#34;实质证据有效性&#34;的积极进展。在收集剩余的有效性数据后，该公司再向 FDA 申请完全批准。FDA 审核申请，并在适当的情况下完全批准该药物。</p>
</div><p><strong>About Canalevia®-CA1</strong></p>
<div class="lb-trans"><p><strong>关于 Canalevia®-CA1</strong></p>
</div><p>Canalevia-CA1 contains crofelemer, Jaguar's novel, oral plant-based drug sustainably harvested from the <em>Croton lechleri</em> tree, that modulates chloride channels in the gastrointestinal tract to reduce diarrhea. Importantly, Canalevia is not an antibiotic drug. The overuse and misuse of antibiotics, both in humans and animals, contribute to the development of bacteria that are resistant to antibiotics. Canalevia-CA1, currently conditionally approved by the FDA under application number 141-552, is a tablet that can be given orally twice a day for up to three days and can be used for home treatment of CID in dogs.</p>
<div class="lb-trans"><p>Canalevia-CA1 含有 crofelemer，这是 Jaguar 从_Croton lechleri_树上可持续采集的创新植物药，能够调节胃肠道中的氯通道以减少腹泻。重要的是，Canalevia 并不是抗生素药物。抗生素在人体和动物中的过度使用和误用导致了抗生素耐药菌的产生。Canalevia-CA1 目前在 FDA 的申请编号 141-552 下获得条件性批准，是一种可以口服给药的片剂，每天可服用两次，最多可持续三天，可用于犬类 CID 的家庭治疗。</p>
</div><p><strong>About Chemotherapy-induced Diarrhea (CID) in Dogs</strong></p>
<div class="lb-trans"><p><strong>关于犬类化疗引起的腹泻（CID）</strong></p>
</div><p>According to the American Veterinary Medical Association, approximately 1 in 4 dogs will at some stage in their life develop cancer. Nearly half of dogs over 10 will develop cancer.1 According to the National Cancer Institute at the National Institutes of Health, roughly 6 million new cancer diagnoses are made in dogs yearly in the US.</p>
<div class="lb-trans"><p>根据美国兽医医学协会的数据显示，约四分之一的犬类在其生命的某个阶段会发展为癌症。近一半的 10 岁以上犬类会发展为癌症。根据美国国立卫生研究院的国家癌症研究所，每年在美国约有 600 万只犬类被诊断为新癌症。</p>
</div><p>Due to the increasing number of chemotherapeutic agents, chemotherapy is fast becoming the most widely used cancer treatment in veterinary medicine. Studies have found the incidence of CID to be one of the three most prevalent side effects in dogs undergoing cancer treatment,2 and managing side-effects such as diarrhea can be important to maintain successful cancer treatment. More than half of the US veterinarians who responded to a Jaguar-sponsored survey reported that CID interferes with their patients' chemotherapy treatment plans, indicating an unmet need for an effective product for the treatment of CID.</p>
<div class="lb-trans"><p>由于化疗药物数量的增加，化疗正迅速成为兽医医学中使用最广泛的癌症治疗方法。研究发现，CID 的发生率是接受癌症治疗的犬类中三种最常见的副作用之一，管理腹泻等副作用对于维持成功的癌症治疗至关重要。超过一半的参与 Jaguar 赞助调查的美国兽医报告称，CID 干扰了他们患者的化疗治疗计划，表明对有效治疗 CID 的产品存在未满足的需求。</p>
</div><p><strong>Important Safety Information About Canalevia®-CA1</strong></p>
<div class="lb-trans"><p><strong>关于 Canalevia®-CA1 的重要安全信息</strong></p>
</div><p>For oral use in dogs only. Not for use in humans. Keep Canalevia-CA1 (crofelemer delayed-release tablets) in a secure location out of reach of children and other animals. Consult a physician in case of accidental ingestion by humans. Do not use in dogs that have a known hypersensitivity to crofelemer. Prior to using Canalevia-CA1, rule out infectious etiologies of diarrhea. Canalevia-CA1 is a conditionally approved drug indicated for the treatment of chemotherapy-induced diarrhea in dogs. The most common adverse reactions included decreased appetite, decreased activity, dehydration, abdominal pain, and vomiting.</p>
<div class="lb-trans"><p>仅供犬类口服使用。不适用于人类。将 Canalevia-CA1（crofelemer 缓释片）放在儿童和其他动物无法接触的安全位置。如人类意外摄入，请咨询医生。不得用于已知对 crofelemer 过敏的犬类。在使用 Canalevia-CA1 之前，排除腹泻的感染性病因。Canalevia-CA1 是一种条件性批准的药物，适用于治疗犬类化疗引起的腹泻。最常见的不良反应包括食欲减退、活动减少、脱水、腹痛和呕吐。</p>
</div><p><strong>Caution:</strong> Federal law restricts this drug to use by or on the order of a licensed veterinarian. Use only as directed. It is a violation of Federal law to use this product other than as directed in the labeling. Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-552.</p>
<div class="lb-trans"><p><strong>注意：</strong> 联邦法律限制该药物仅由持证兽医使用或根据其指示使用。仅按指示使用。违反联邦法律，使用本产品不得与标签指示不符。根据申请编号 141-552，FDA 条件性批准，待完全证明有效性。</p>
</div><p><strong>About the Jaguar Health Family of Companies</strong></p>
<div class="lb-trans"><p><strong>关于 Jaguar Health 公司家族</strong></p>
</div><p>Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.</p>
<div class="lb-trans"><p>Jaguar Health, Inc.（Jaguar）是一家商业阶段的制药公司，专注于开发可持续来源于雨林地区植物的新型专利处方药，旨在为人类和动物提供针对胃肠道不适的治疗，特别是与肠道过度活跃相关的症状，包括慢性虚弱性腹泻、急迫感、肠失禁和痉挛性疼痛。Jaguar 旗下的 Napo Pharmaceuticals（Napo）专注于开发和商业化人用处方药，以支持和管理多种复杂疾病状态下被忽视的胃肠道症状。Jaguar 旗下的 Napo Therapeutics 是一家意大利公司，Jaguar 于 2021 年在意大利米兰成立，专注于扩大 crofelemer 在欧洲的使用，特别是针对孤儿疾病。Jaguar Animal Health 是 Jaguar 的商标名称。Magdalena Biosciences 是 Jaguar 与 Filament Health Corp.共同成立的合资企业，源于 Jaguar 的 Entheogen Therapeutics Initiative（ETI），专注于开发源自植物的针对心理健康的处方药。</p>
</div><p>For more information about:</p>
<div class="lb-trans"><p>有关更多信息：</p>
</div><p>Jaguar Health, visit https://jaguar.health</p>
<div class="lb-trans"><p>Jaguar Health，请访问 https://jaguar.health</p>
</div><p>Napo Pharmaceuticals, visit napopharma.com</p>
<div class="lb-trans"><p>Napo Pharmaceuticals，请访问 napopharma.com</p>
</div><p>Napo Therapeutics, visit napotherapeutics.com</p>
<div class="lb-trans"><p>Napo Therapeutics，请访问 napotherapeutics.com</p>
</div><p>Magdalena Biosciences, visit magdalenabiosciences.com</p>
<div class="lb-trans"><p>Magdalena Biosciences，请访问 magdalenabiosciences.com</p>
</div><p>Canalevia-CA1, visit canalevia.com</p>
<div class="lb-trans"><p>Canalevia-CA1，请访问 canalevia.com</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>Certain statements in this press release constitute &#34;forward-looking statements.&#34; These include statements regarding Jaguar's expectation that the company's ongoing trial will provide the substantial evidence of effectiveness required for full approval of the drug for treatment of CID in dogs and will conclude in February 2026 with an approximate total of 100 dogs having participated. In some cases, you can identify forward-looking statements by terms such as &#34;may,&#34; &#34;will,&#34; &#34;should,&#34; &#34;expect,&#34; &#34;plan,&#34; &#34;aim,&#34; &#34;anticipate,&#34; &#34;could,&#34; &#34;intend,&#34; &#34;target,&#34; &#34;project,&#34; &#34;contemplate,&#34; &#34;believe,&#34; &#34;estimate,&#34; &#34;predict,&#34; &#34;potential&#34; or &#34;continue&#34; or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.</p>
<div class="lb-trans"><p>本新闻稿中的某些声明构成 “前瞻性声明”。这些包括关于 Jaguar 期望公司正在进行的试验将提供治疗犬类 CID 所需的有效性充分证据的声明，并预计将在 2026 年 2 月结束，参与犬只总数约为 100 只。在某些情况下，您可以通过诸如 “可能”、“将”、“应该”、“期望”、“计划”、“目标”、“预期”、“能够”、“打算”、“针对”、“项目”、“考虑”、“相信”、“估计”、“预测”、“潜在” 或 “继续” 等术语或这些术语的否定形式或其他类似表达来识别前瞻性声明。本声明中的前瞻性声明仅为预测。Jaguar 在很大程度上基于其当前的期望和对未来事件的预测来制定这些前瞻性声明。这些前瞻性声明仅在本声明发布之日有效，并且受到多种风险、不确定性和假设的影响，其中一些无法预测或量化，某些超出了 Jaguar 的控制范围。除非法律要求，Jaguar 不打算公开更新或修订本声明中包含的任何前瞻性声明，无论是由于任何新信息、未来事件、情况变化或其他原因。</p>
</div><p>1 &#34;Cancer in Pets.&#34; American Veterinary Medical Association, 2021, https://www.avma.org/resources/pet-owners/petcare/cancer-pets</p>
<div class="lb-trans"><p>1 &#34;宠物中的癌症。&#34; 美国兽医医学协会，2021 年，https://www.avma.org/resources/pet-owners/petcare/cancer-pets</p>
</div><p>2 Mason SL, Grant IA, Elliott J, Cripps P, Blackwood L. Gastrointestinal toxicity after vincristine or cyclophosphamide administered with or without maropitant in dogs: a prospective randomised controlled study. J Small Anim Pract. 2014;55:391-398</p>
<div class="lb-trans"><p>2 Mason SL, Grant IA, Elliott J, Cripps P, Blackwood L. 在犬只中使用或不使用 maropitant 后，vincristine 或 cyclophosphamide 引起的胃肠道毒性：一项前瞻性随机对照研究。J Small Anim Pract. 2014;55:391-398</p>
</div><p><strong>Contact:</strong></p>
<div class="lb-trans"><p><strong>联系方式：</strong></p>
</div><p>hello@jaguar.health</p>
<div class="lb-trans"><p>hello@jaguar.health</p>
</div><p>Jaguar-JAGX</p>
<div class="lb-trans"><p>Jaguar-JAGX</p>
</div><p><strong>SOURCE:</strong> Jaguar Health, Inc.</p>
<div class="lb-trans"><p><strong>来源：</strong> Jaguar Health, Inc.</p>
</div><p>View the original press release on ACCESS Newswire</p>
<div class="lb-trans"><p>查看原始新闻稿，请访问 ACCESS Newswire</p>
</div>

FDA 批准续期 Jaguar Health 的药物 Canalevia-CA1，该药用于治疗犬化疗引起的腹泻（CID）